Motivation: The SYNERGY trial SYNERGY protocol:
• Study drug to be continued until treating physician deemed no further anticoagulation required -"treatment completion "
• Study drug to be mandatorily discontinued if bleeding , other adverse events , thrombocytopenia , need for CABG, . . .
Optional discontinuation: In the trial
• Some subjects stopped assigned study drug for reasons not sanctioned by protocol (e.g., MD or patient preference, etc)
• Some subjects switched (crossed over ) to the other drug; not sanctioned by protocol
Motivation: The SYNERGY trial
Results: Intent-to-treat analyses
• Analysis of 1 year death: hazard ratio 1.06 (0.92-1.22)
• Contradicts previous findings showing ENOX superior to UFH
• Higher risk , more aggressively managed patient population?
• Discontinuation ? 24.4% (13.2% optional , 11.3% mandatory ) of ENOX subjects vs. 14.4% (7.5% optional , 6.9% mandatory ) of UFH subjects
Question: "What would have been the difference in UFH and ENOX survival distributions had no subject discontinued his/her assigned treatment ?"
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Motivation: The SYNERGY trial Proposed analyses:
• Delete all subjects discontinuing assigned study drug for any reason from the data set, do standard analysis
• Artificially censor outcomes for all subjects discontinuing assigned study drug for any reason at the times of discontinuation , do standard analysis
• Fit a proportional hazards (PH) model with binary time-dependent on/off indicators for each treatment Question: "What would have been the difference in UFH and ENOX survival distributions had no subject discontinued his/her assigned treatment ?"
• What is really meant by this?
• Do any of these analyses address it?
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Motivation: The SYNERGY trial Our objective: An instructive demonstration of how to conceptualize this problem
• More precise statement of the question
• Statistical framework
• =⇒ Inverse probability risk set weighting (Robins and Rotnitzky, 1992; Robins, 1993; Hernán et al., 2006) Ideal goal: "Difference in survival distributions were all subjects in the population to follow each of the treatment regimens studied"
"Following" a treatment regimen:
• There are circumstances where discontinuation of regimen is mandatory, e.g., adverse event (safety , ethical reasons), CABG
• =⇒ Mandatory discontinuation is consistent with how treatment is intended to or must be administered
• =⇒ "Following " should acknowledge this
Optional discontinuation:
• Is not consistent with how treatment is intended to or must be administered
• Should thus be distinguished from mandatory discontinuation Conceptualization Question, better stated: "What would have been the difference in survival distributions corresponding to the treatment regimes for ENOX and UFH had no subject discontinued his/her assigned treatment for optional reasons ?"
• Do the analyses mentioned previously address this?
• Problem : All are ad hoc , none arise explicitly from addressing this goal. . .
Better idea: Define a statistical framework in which the treatment effect of interest corresponding to this question can be defined formally =⇒ suggest valid inferential methods
Statistical framework
Situation: As in SYNERGY
• Time-to-event outcome up to t max (e.g., 1 year)
• Outcomes administratively censored at t max First step: Characterize the ideal situation with no optional discontinuation through t max
• Treatment regimes z = 0 (UFH) and 1 (ENOX)
• "Continue on z until completion or event meriting mandatory discontinuation"
Ideal observed data: (POTENTIAL OUTCOMES) For a trial with n subjects and no optional discontinuations Pr{t ≤ T * < t + h|T * ≥ t, Z} = λ 0 (t) exp(βZ)
• β = log hazard ratio for regime 1 to regime 0 Statistical framework Inference on β: Assume T * ⊥ ⊥C *
|Z
• Solve for β the partial likelihood score equation
Statistical framework Actual observed data: Some subjects optionally discontinue
• Time to failure/censoring U i ; censoring indicator ∆ i = 1 if failure, = 0 if censoring
= time of "first thing " to happen
Statistical framework
The problem:
• So, for some subjects, only partial information on hazard for T *
• =⇒ Standard analysis using (U i , ∆ i ) in place of (U * i , ∆ * i ) for inference on β may not apply. . .
Inference Standard analysis: Solve in
Modification: Weight contributions of subjects in each risk set who
have not yet optionally discontinued assigned treatment
for u < S * , otherwise, q(u, W * ) = 0 because no possibility of being observed to optionally discontinue once mandatory discontinuation, censoring or failure has occurred Inference Critical assumption: For consistent estimation of β • Similar to "missing at random "
• I.e., the hazard at time u depends on (W * ) when u < S * only through the data Z, Q(u) observed to time u
• Plausible -decision to optionally discontinue likely based on subject characteristics and experience up to time u
• Issue -Was all relevant information captured in the trial and hence available in Q(u)?
denotes the probability of not being optionally discontinued by time u or by time to mandatory discontinuation.
• "Observed data " counting process increment
• Can be shown : Leads to unbiased estimating equation Implementation 1. Fit model for q{u, Z, Q(u)}, the hazard of optionally discontinuing (e.g., proportional hazards model with time-dependent covariates)
2. For each i and u equal to every distinct event time, estimate K{u, Z, Q(·), S}; e.g., using Breslow's estimator 3. For each i, create weights at each distinct event time u equal to 0 if i optionally discontinued by u or using the estimates from step 2 if not 4. Substitute weights in the modified score equations and solve for β
Step 4: May be implemented in SAS proc phreg
• Counting process input format
• weight statement
• cov(aggregate) option
• "Robust " output standard errors will be conservative but work well
Discussion
• Sensible conceptualization of "treatment effect had no subject discontinued his/her assigned treatment"
• Critical : Distinguish optional vs. mandatory discontinuation, focus on treatment regimes
• =⇒ Should collect reasons for discontinuation and covariates that may be associated with decisions
• Justification of inverse probability risk set weighting
• "The analysis that would have been done" under the standard assumption of independent censoring if there were no optional discontinuation
• Key assumption : Optional discontinuation depends on potential outcomes only through the observed data "missing at random" 
